ChemotherapyFDA-approvedFirst-line
Carboplatin + Paclitaxel
Generic name: carboplatin, paclitaxel
How it works
Interferes with cell division, causing cancer cells to die.
Cancer types
Lung Cancer— All patients
Efficacy
In clinical trials, carboplatin and paclitaxel improved response rates and survival in patients with non-small cell lung cancer.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Ovarian Cancer Treatment Study Finds Key Prognostic Factors | Ovarian Cancer | preclinical | Median progression-free survival was 20.8 months, and median overall survival was 41.1 months. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.